Literature DB >> 2329258

Comparison of RA 131I treatment protocols for Graves' disease.

L J DeGroot1, A Mangklabruks, M McCormick.   

Abstract

The efficacy of 131I therapy in achieving euthyroidism has been studied in a group of 264 patients followed for up to 10 yr. One hundred and eighty-six were given a dose adjusted for thyroid size and radioactive iodine uptake (Protocol 1), and a second group received the same dosage followed by antithyroid drug therapy plus potassium iodide for 15 days (Protocol 2). At 10-yr follow-up, 50-60% of patients were euthyroid. 25-29% of patients required 2 doses of 131I, and 4-5% required 3 doses. Fewer patients became hypothyroid when their pretreatment FTI was above the average value. More patients became hypothyroid, if their pretreatment test for antimicrosomal antibodies was positive. Patients who required a second dose of radioactive iodide had a significantly greater chance of having worsening of their ophthalmopathy than those who became hypothyroid after the first dose. Treatment with radioactive iodide under either protocol appears to achieve euthyroidism at 10 yr with an incidence higher than that achieved by antithyroid drugs and comparable to that reported for subtotal thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2329258     DOI: 10.1007/bf03349519

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Effect of pretreatment with methylthiouracil on results of I-131 therapy.

Authors:  J CROOKS; W W BUCHANAN; E J WAYNE; E MACDONALD
Journal:  Br Med J       Date:  1960-01-16

2.  Comparison of high and low dosage levels of 131-I in the treatment of thyrotoxicosis.

Authors:  G A Hagen; R P Ouellette; E M Chapman
Journal:  N Engl J Med       Date:  1967-09-14       Impact factor: 91.245

3.  Hypothyroidism after low-dose 131 I treatment of hyperthyroidism.

Authors:  J A Glennon; E S Gordon; C T Sawin
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

4.  Clinical trial of different doses of 131-I in treatment of thyrotoxicosis.

Authors:  R N Smith; G M Wilson
Journal:  Br Med J       Date:  1967-01-21

5.  Rapid control of thyrotoxicosis with combined 131I, anthithyroid drugs and KI therapy.

Authors:  S Refetoff; N Demeester-Mirkine; A M Ermans; L J DeGroot
Journal:  J Nucl Med Allied Sci       Date:  1977 Jan-Jun

6.  Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism.

Authors:  D S Ross; G H Daniels; P De Stefano; F Maloof; E C Ridgway
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

7.  Compensated low-dose 131I therapy of Graves' disease.

Authors:  C P Roudebush; K E Hoye; L J DeGroot
Journal:  Ann Intern Med       Date:  1977-10       Impact factor: 25.391

8.  Outcome of patients with Graves' disease after long-term medical treatment guided by triiodothyronine (T3) suppression test.

Authors:  M Yamamoto; Y Totsuka; I Kojima; N Yamashita; K Togawa; N Sawaki; E Ogata
Journal:  Clin Endocrinol (Oxf)       Date:  1983-10       Impact factor: 3.478

9.  Relapses after thionamide therapy for Graves' disease.

Authors:  L E Holm; I Alinder
Journal:  Acta Med Scand       Date:  1982

10.  Effect on exophthalmos of various methods of treatment of Graves' disease.

Authors:  G Gwinup; A N Elias; M S Ascher
Journal:  JAMA       Date:  1982-04-16       Impact factor: 56.272

View more
  7 in total

Review 1.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

Review 2.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

Review 3.  Risk factors for development or deterioration of Graves' ophthalmopathy.

Authors:  Marius N Stan; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

4.  Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography.

Authors:  M Tsuruta; Y Nagayama; N Yokoyama; M Izumi; S Nagataki
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

5.  Association between radioiodine therapy for Graves' hyperthyroidism and thyroid-associated ophthalmopathy.

Authors:  Samer El-Kaissi; Joanne Bowden; Margaret J Henry; Myra Yeo; Bernard L Champion; Peter Brotchie; Geoffrey C Nicholson; Jack R Wall
Journal:  Int Ophthalmol       Date:  2010-04-20       Impact factor: 2.031

6.  A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism.

Authors:  Suhail AR Doi; Issa Loutfi; Kamal AS Al-Shoumer
Journal:  BMC Nucl Med       Date:  2001

7.  The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves' Disease and the Predictive Factors Influencing its Development.

Authors:  Maha Abd El-Kareem El-Sayed Husseni
Journal:  World J Nucl Med       Date:  2016 Jan-Apr
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.